PT  - JOURNAL ARTICLE
AU  - Johnson, Christoph
AU  - Ferguson, Kirvina
AU  - Smith, Tavion
AU  - Wallace, Dashaunette
AU  - McConnell, Keith
AU  - Conserve, Donaldson
AU  - Martin, Indira
TI  - EVALUATION OF THE PANBIO SARS-COV-2 RAPID ANTIGEN DETECTION TEST IN THE BAHAMAS
AID  - 10.1101/2021.07.13.21260402
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.13.21260402
4099  - http://medrxiv.org/content/early/2021/07/15/2021.07.13.21260402.short
4100  - http://medrxiv.org/content/early/2021/07/15/2021.07.13.21260402.full
AB  - Identification and isolation of persons infected with SARS-COV-2 are key mitigation strategies in the current pandemic, and rapid antigen detection tests (RADTs) offer the promise of decreased turnaround time to diagnosis when compared with gold standard RT-PCR testing. We evaluated the analytical performance of the Abbott® Panbio™ RADT on nasopharyngeal samples stored at the Ministry of Health National Reference Lab in Nassau, Bahamas. The Panbio™ demonstrated a test sensitivity of 94% and a specificity of 100% on 50 PCR negative samples and 50 samples presumed to be infectious based on having PCR cycle threshold values below 30. Additionally, in our examination of operator results there was low interpersonal variation (1%) among three blind operators and significant correlation between sample Ct value and perceived signal strength on the RADT device. However, three PCR positive samples below Ct 30 were misdiagnosed by RADT, including one sample with Ct value less than 20. These results support the use of the Panbio™ in symptomatic persons to detect active SARS-COV-2 infections, with the caveat that RADT-negative samples should be confirmed by RT-PCR.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTest products were donated by Dynamic Health Services, Bahamas; all other funding received via the Bahamas Ministry of HealthAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Bahamas National Covid Ethics Committee, The Ministry of HealthAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data not contained in the manuscript are available upon request